Aether Industries Limited share price
NSE: AETHER · ISIN INE0BWX01014
Key numbers
- Market cap
- ₹ 23,453 Cr
- Current price
- ₹ 1,767.00
- 52-week high / low
- ₹ 1,798 / 728
- Stock P/E
- 92.6
- Book value
- ₹ 185.1
- Dividend yield
- 0.00%
- ROCE
- 11.6%
- ROE
- 9.4%
- Debt to equity
- 0.19
- Sales growth (3 yrs)
- 20.2%
- Profit growth (3 yrs)
- 18.9%
- 1-year return
- 139.8%
About Aether Industries Limited
Aether Industries Limited produces and sells advanced intermediates and specialty chemicals in India and internationally. It provides large-scale manufacturing, contract research and manufacturing services, as well as contract/exclusive manufacturing services. The company serves its products to the chemical industry, including multinational, regional, and local companies in the pharmaceuticals, agrochemicals, materials science, coatings, photography, additives, and oil and gas industries. It also exports its products. The company collaborate with Dow Chemical International Private Limited to manufactures silicone technology development in India. Aether Industries Limited was incorporated in 2013 and is headquartered in Surat, India.
Quarterly results
Consolidated figures in ₹ crores
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 257 | 275 | 317 | 305 | 327 |
| Operating profit | 81 | 88 | 111 | 83 | 103 |
| Net profit | 47 | 54 | 64 | 54 | 63 |
| EPS (₹) | 3.55 | 4.07 | 4.86 | 4.07 | 4.77 |
Concall summary (2026-08-07)
AI summary of the earnings call transcript · tone: Positive · source document
Guidance & outlook
- The consolidated revenue for Q1 of FY27 has Aether Industries Limited July 31, 2026 increased by 27% year-over-year, and it has reached INR3,266 million in this quarter as against INR2,566 million in Q1 of FY26.
- The EBITDA has reached INR1,028 million in Q1 FY27, as against INR785 million in Q1 of FY26, which is an increase of 31% year-over-year.
Growth & demand
- In financial year 2027, the demand signal is the strongest we have ever seen from order visibility, rising urgencies from customers in the West, and the CRAMS to CEM conversion pipelines that keep deepening.
- Our core specialty and CRAMS plus CEM business is delivering 25% to 30% compounding growth you have come to expect.
Margins & costs
- CEM runs at EBITDA margins north of 28% to 30%, so every point of mix that shifts towards this model makes our earnings both larger and more resilient.
- EBITDA margins stood at 31% in this Q1 of FY27 as against 30% in Q1 FY26.
Capex & expansion
- The centerpiece of our capacity story is Magnum, which is the name for our Site 5 in Panoli, a mega site with 16 production blocks commissioned in phases.
- The total capex for Q1 of FY27 was INR943 million.
Balance sheet & cash
- We remain fully cognizant on the working capital discipline, and its sustained reduction continues to be a clear operational priority.
- While overall working capital intensity has improved, inventory levels remain elevated, primarily reflecting strategic ra w material positioning and semi-finished materials for Site 3++ and Site 5.
Peers in Specialty Chemicals
Data for information only, not investment advice. Prices end of day.